Peter Richardson was a co-founder of BenevolentAI, and since 2018 he has served as VP
Pharmacology in BenevolentAI. He was a founding member of Cambridge Biotechnology
Ltd in 2001 and served as CSO and Executive Director until 2009, while also being EVP and
Head of Discovery in Biovitrum from 2005. Between 2009 and 2018 he served as an adviser
to Proximagen, Upsher Smith and BenevolentAI. In 2020 he was responsible for the
identification of baricitinib as a therapy for COVID-19.
Peter J Richardson
